Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Sep 14 · above the Ichimoku cloud · RSI 48 · MACD below its signal
| 1.80 | 52-week high | +620.00% |
| 1.28 | Previous month high | +414.00% |
| 1.26 | R3 (classic) | +406.00% |
| 1.07 | R2 (classic) | +330.00% |
| 0.9800 | R1 (classic) | +292.00% |
| 0.9700 | Previous week high | +288.00% |
| 0.8850 | Previous day high | +254.00% |
| 0.7900 | Pivot | +216.00% |
| 0.6950 | S1 (classic) | +178.00% |
| 0.6000 | Previous day low | +140.00% |
| 0.5050 | S2 (classic) | +102.00% |
| 0.4100 | S3 (classic) | +64.00% |
| 0.2500 | Price now | |
| 0.1610 | Previous month low | −35.60% |
| 0.1100 | Previous week low | −56.00% |
| 0.001000 | 52-week low | −99.60% |
None of the 29 investors followed here reported a position in EGRX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a EGRX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for EGRX.
TimeframesUp on the weekly, down on the monthly, mixed on the daily.
pulling back under the 21 EMA
over a rising 21 EMA, 21 over 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -64.3 | -40.0 | 127.3 | 39.3 | 21.1 | 16.5 | -44.8 | 150.0 | 2.7 | -6.8 | +26.4% | ||
| 2025 | 60.0 | 50.0 | -18.3 | 100.0 | -3.1 | 52.6 | 27.2 | -16.3 | -12.6 | -74.1 | -28.6 | 40.0 | +40.0% |
| 2024 | 12.0 | 0.0 | -10.6 | -21.9 | -15.2 | 61.4 | -13.9 | 6.6 | -27.4 | -83.9 | 18.3 | -29.6 | −90.4% |
| 2023 | 16.1 | -17.5 | 1.3 | -1.0 | -26.1 | -6.3 | 6.8 | -18.4 | -7.0 | -12.9 | -57.4 | -10.6 | −82.1% |
| 2022 | -9.8 | 3.2 | 4.4 | -10.8 | 5.8 | -4.9 | -10.6 | -17.5 | -19.4 | 19.1 | 15.4 | -19.5 | −42.6% |
| 2021 | 0.2 | -4.6 | -6.2 | -2.2 | -3.0 | 8.0 | 8.6 | 14.8 | 4.5 | -6.1 | -9.0 | 6.8 | +9.3% |
| 2020 | -10.4 | -14.7 | 0.2 | 10.8 | 0.5 | -6.4 | -3.3 | -14.5 | 7.1 | 9.5 | -2.2 | 2.4 | −22.5% |
| 2019 | 4.9 | 18.5 | 0.8 | 1.8 | -1.2 | 9.6 | -1.5 | 2.8 | 0.3 | 10.8 | -6.7 | 2.7 | +49.1% |
| 2018 | 11.9 | -6.1 | -6.1 | -1.3 | 29.6 | 12.2 | 4.7 | -12.8 | 0.3 | -29.0 | 2.4 | -20.1 | −24.6% |
| 2017 | -12.8 | 10.8 | 8.1 | 9.2 | -19.5 | 8.1 | -37.7 | 11.0 | 9.3 | -9.9 | 9.9 | -9.5 | −32.7% |
| 2016 | -18.9 | -11.8 | -36.1 | -6.5 | 25.5 | -18.4 | 11.2 | 38.5 | 17.2 | -20.2 | 41.3 | 0.5 | −10.5% |
| 2015 | 25.2 | 75.2 | 23.2 | 25.8 | 37.8 | 11.3 | 19.5 | -18.7 | -5.8 | -13.9 | 43.8 | -3.2 | +472.1% |
| 2014 | -7.3 | -22.7 | 20.2 | 20.9 | -20.7 | 10.9 | 0.4 | 0.2 | -0.5 | 22.9 | +12.6% |
No analyst coverage for this instrument.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
No recent headlines.